SCHEMBL1714252

SCHEMBL1714252

Cc1cnc2[nH]cc(C=C3N=C(N4CCCCC4)NC3=O)c2c1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 7/20 0.44
▸ DYRK2 Q92630 7/20 0.44
▸ DYRK3 O43781 6/20 0.44
▸ PIM1 P11309 6/20 0.44
▸ DYRK1B Q9Y463 6/20 0.44
▸ CSNK2A2 P19784 3/20 0.44
▸ CSNK2B P67870 3/20 0.44
▸ CSNK2A1 P68400 3/20 0.44
▸ CSNK2A3 Q8NEV1 3/20 0.44
▸ MAP4K1 Q92918 1/20 0.36
▸ BRD4 O60885 2/20 0.34
▸ ROCK2 O75116 2/20 0.32
▸ ROCK1 Q13464 2/20 0.32
▸ CDC42BPB Q9Y5S2 2/20 0.32
▸ CNR1 P21554 2/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ CDC42BPA Q5VT25 1/20 0.31
▸ IP6K1 Q92551 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1714454 1.00 DYRK1A (0.44) DYRK1ADYRK2DYRK3PIM1DYRK1B
SCHEMBL1714456 1.00 DYRK1A (0.44) DYRK1ADYRK2DYRK3PIM1DYRK1B
SCHEMBL1714248 1.00 DYRK1A (0.44) DYRK1ADYRK2DYRK3PIM1DYRK1B
SCHEMBL1714018 0.88 DYRK1A (0.44) DYRK1ADYRK2DYRK3PIM1DYRK1B
SCHEMBL1713456 0.88 DYRK1A (0.44) DYRK1ADYRK2DYRK3PIM1DYRK1B
SCHEMBL1714354 0.88 DYRK1A (0.44) DYRK1ADYRK2DYRK3PIM1DYRK1B
SCHEMBL1714705 0.88 DYRK1A (0.44) DYRK1ADYRK2DYRK3PIM1DYRK1B
SCHEMBL1714703 0.88 DYRK1A (0.44) DYRK1ADYRK2DYRK3PIM1DYRK1B
SCHEMBL1713459 0.88 DYRK1A (0.44) DYRK1ADYRK2DYRK3PIM1DYRK1B
SCHEMBL1714083 0.87 DYRK3 (0.40) DYRK1ADYRK2DYRK3PIM1DYRK1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8314121-B2 Imidazolone derivatives, preparation thereof as drugs, pharmaceutical compositions, and use thereof as protein kinase inhibitors, in particular CDC7 SANOFI (FR) 2012-11-20 — — US disclosed
EP-2094699-B1 NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 SANOFI AVENTIS (FR) 2011-07-20 — — EP disclosed
US-20090253679-A1 NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 SANOFI-AVENTIS (FR) 2009-10-08 — — US disclosed
EP-2094699-A2 NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 Sanofi-Aventis (FR) 2009-09-02 — — EP disclosed
WO-2008046982-A2 NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 SANOFI-AVENTIS (FR) 2008-04-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253679-A1 NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 CDC7, CDK7, CDK17 DYRK1A 987/4885DYRK2 792/4885DYRK3 1123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback